Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded
Researchers in the UK are hoping to develop a rapid, saliva-based test that could identify stroke patients who need rapid treatment to prevent irreversible brain damage.
Swiss biotech Idorsia has suffered a setback in its bid to develop clazosentan for a form of stroke in the west, despite winning approval of the drug in Japan last year.